Market's view on Tissue Regenix Group
Published on April 2024
- Anticipation of a stock price increase following upcoming updates on continuous sales growth in Europe and the USA.
- Highlighting the challenge of funding needs for early-stage biotech companies, though current cash reserves are reportedly adequate.
- Mention of year-end presentation for December 2023 and its implications.
- Observations of market dynamics where limited availability can lead to significant impacts from even minor demand increases.
- Discussion on market makers potentially being short on stock, leading to potential market manipulation tactics like ‘tree shaking.’
- Comments on selling activities post-news announcements, with expectations of a continuing upward trend in results.
- Inquiries and discussions about the reasons behind a significant stock price drop.
- Advice on finding value in small-cap stocks with a recommendation to buy and hold for 18-24 months.
- Reaction to an unexpected stock drop, speculating on outcomes if the financial results had been worse.
- Strategy discussions on buying during perceived undervalued periods in anticipation of future gains.
- Expectations set for a steady stock price rise within the year.
- Speculation on potential corporate activities following unusual late trading patterns.
- Technical analysis focusing on important price points and volumes for trading decisions.
- Query about potential significant upcoming news announcements.
- Positive news shared about a European distribution deal.
- Forecasting specific short-term price targets based on technical analysis.
- Observations on technical indicators suggesting a positive trend reversal not seen since 2017.